# Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

> **NCT05357482** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 40 (actual)

## Conditions studied

- Sickle Cell Anemia
- Beta Thalassemia

## Interventions

- **RADIATION:** TBI
- **DRUG:** Hydroxyurea
- **BIOLOGICAL:** briquilimab
- **DRUG:** Filgrastim (G-CSF)
- **DRUG:** Sirolimus
- **BIOLOGICAL:** Alemtuzumab
- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT05357482
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-12
- **Primary completion:** 2026-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357482, "Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05357482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*